fa بررسی میزان و طول مدت تاثیر سندوستاتین طولانی اثر در درمان بیماران مبتلا به آکرومگالی مقاله پژوهشی Original Research Article <div style="text-align: justify;"><span style="color:#ffffff;"><span style="font-size:18px;"><span style="font-family:Times New Roman;"><strong><span style="background-color:#16a085;">Background:</span></strong></span></span></span><span style="font-size:16px;"><span style="font-family:Times New Roman;"> Pharmacotherapy of acromegaly has been successful in recent years. The therapeutic efficacy of long-acting sandostatin in the treatment of acromegaly has been established in multiple studies. In this report, we investigated the effectiveness of multiple injections of sandostatin and its acting period in Tehran in 2001. </span></span><br> <span style="font-size:18px;"><span style="font-family:Times New Roman;"><strong><span style="color:#ffffff;"><span style="background-color:#16a085;">Materials and Methods:</span></span></strong></span></span><span style="font-size:16px;"><span style="font-family:Times New Roman;"> In this Quasi-experimental study five diagnosed patients with acromegaly after hypophysectomy were treated with sandostatin LAR and followed up for at least 63 days after injection. After octreotide test, a dose of 30 mg sandostatin was prescribed for 3 injections. Frequency of mean daily growth hormons (GH) less than 5&micro;g/L were compared after the first and the third injections. Then acting time of the drug was assessed. The efficacy of 30 and 40 mg doses were compared in 3 cases. </span></span><br> <strong><span style="font-size:18px;"><span style="font-family:Times New Roman;"><span style="color:#ffffff;"><span style="background-color:#16a085;">Results:</span></span></span></span></strong><span style="font-size:16px;"><span style="font-family:Times New Roman;"> There was no relationship between response rate to octreotide and sandostatin. Frequency of GH<5&micro;g/L after the third injection was higher than that of the first one (P<0.01). Therapeutic effect of the drug continued for 42 days after the treatment in responding patients. </span></span><br> <strong><span style="font-size:18px;"><span style="font-family:Times New Roman;"><span style="color:#ffffff;"><span style="background-color:#16a085;">Conclusion:</span></span></span></span></strong><span style="font-size:16px;"><span style="font-family:Times New Roman;"> Octreotide test (with single dose injection) is not a good method for prediction of patients&#39; response to treatment. Measuring GH after multiple injections is a better method for this purpose. Drug injection interval should be determined separately for each patient.</span></span></div> ACROMEGALY, SANDOSTATIN LAR, GROWTH HORMONE 31 36 http://journal.zums.ac.ir/browse.php?a_code=A-10-1-118&slc_lang=fa&sid=1 Sima Hashemipour سیما هاشمی پور 5200319475328460070069 5200319475328460070069 Yes Bagher Larijani باقر لاریجانی 5200319475328460070070 5200319475328460070070 No Rza Baradarjalili رضا برادر جلیلی 5200319475328460070071 5200319475328460070071 No Mohammadreza Mohajeri محمد رضا مهاجری 5200319475328460070072 5200319475328460070072 No